DMX-200 for FSGS has orphan drug status which comes with a streamlined trial process that is compressed and therefore faster and cheaper, and well within Dimerix's capability to run. DMX-200 for DKD on the other hand will require a much longer and larger trial process that will take years and considerable expense to complete.
So the rationale would be for Dimerix to do the FSGS trials in-house without having to share any eventual revenue with a partner. This could be funded by further (modest) capital raises, or better still with upfront fees obtained from a Big Pharma partner who takes on the DKD Phase 3 trial in exchange for a share of future revenue. If the FSGS trial is successful, revenue will flow more quickly and fund future activities (such as DMX-700 development and perhaps dividends to shareholders).
- Forums
- ASX - By Stock
- DXB
- Ann: Quarterly Appendix 4C and Activities Report
Ann: Quarterly Appendix 4C and Activities Report, page-214
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
61.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $335.3M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 18064 | 61.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
59.0¢ | 4000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 18064 | 0.615 |
8 | 9332 | 0.610 |
3 | 165687 | 0.605 |
9 | 237280 | 0.600 |
2 | 19224 | 0.595 |
Price($) | Vol. | No. |
---|---|---|
0.590 | 4000 | 1 |
0.600 | 38500 | 2 |
0.605 | 5018 | 2 |
0.610 | 39062 | 1 |
0.615 | 17339 | 1 |
Last trade - 09.45am 21/06/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
Day chart unavailable
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Chairman
Nick Poll
Executive Chairman
Previous Video
Next Video
SPONSORED BY The Market Online